论文部分内容阅读
目的评价三株抗卵巢上皮癌相关抗原单抗ＣＯＣ１６６－９、１８３Ｅ、１８３Ｆ１联合和单一检测肿瘤标志物的价值，尤其是对卵巢良恶性肿瘤的鉴别。方法单抗ＣＯＣ１６６－９、１８３Ｅ、１８３Ｆ１免疫组化方法检测了卵巢上皮癌８３例、卵巢良性肿瘤４６例，四格表法统计出四项诊断指标值。结果随着单抗联合数量的增多，诊断卵巢癌的特异性由９１．３％上升到９７．８％（二种联合）直至１００％（３种联合），假阳性率降为０。结论多项肿瘤标志物联合检测可提高特异性，降低假阳性率。单抗ＣＯＣ１６６－９、１８３Ｅ、１８３Ｆ１联合检测对卵巢上皮癌尤其是卵巢良恶性肿瘤更具鉴别诊断意义。
OBJECTIVE: To evaluate the value of COC166-9, 183E1 and 183F1 combined with monoclonal antibodies against ovarian epithelial carcinoma associated antigen and single tumor markers, especially for the identification of benign and malignant ovarian tumors. Methods Monoclonal antibodies COC166-9,183E and 183F1 were used to detect 83 cases of epithelial ovarian cancer and 46 cases of ovarian benign tumor by immunohistochemistry. Results With the increase of the number of monoclonal antibodies, the specificity of diagnosis of ovarian cancer increased from 91.3% to 97.8% (two kinds of combination) up to 100% (three kinds of combination), and the false positive rate dropped to zero. Conclusion Combined detection of multiple tumor markers can improve the specificity and reduce the false positive rate. McAb COC166-9,183E, 183F1 combined detection of ovarian epithelial cancer, especially benign and malignant ovarian tumors more differential diagnosis.